Activates natriuretic peptide receptor A (NPR-A, particulate guanylate cyclase), elevating cGMP to cause vasodilation and natriuresis.
Reference facts
- Also known as
- Carperitide, α-ANP, ANF
- Category
- Cardiovascular & Natriuretic
- Mechanism of action
- Activates natriuretic peptide receptor A (NPR-A, particulate guanylate cyclase), elevating cGMP to cause vasodilation and natriuresis.
- Targets
- NPR-A (GC-A)
- Indications under research or approved
- Acute decompensated heart failure (Carperitide approved Japan)
- Regulatory status (reference entry)
- Not FDA-approved (BNP analog Nesiritide was, but withdrawn 2018)
- Half-life
- ~3 minutes
- Sequence
- SLRRSSCFGGRMDRIGAQSGLGCNSFRY
- Sequence notes
- 28-residue cardiac peptide with disulfide bridge Cys7-Cys23 forming the characteristic 17-residue ring.
- Molecular weight (Da)
- 3081
- PDB accession
- 1ANP
- First reported
- 1981
Primary References
Explore research articles about Atrial Natriuretic Peptide (ANP)
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.